# Oramed Pharmaceuticals Inc.: Form 10-Q for the period ended Nov 30, 2021

- Company: [Oramed Pharmaceuticals Inc.](/companies/ormp.md) (CIK 1176309)
- Form: 10-Q
- Filed: 2022-01-11
- Accepted by EDGAR: Jan 11, 2022, 16:45 ET
- Period: 2021-11-30
- Accession: 0001213900-22-001563
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1176309/000121390022001563/f10q1121_oramedpharma.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1176309/000121390022001563/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-11-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-09-01 to 2021-11-30 | $674.0k | us-gaap:Revenues |
| Research and development | 3 months, 2021-09-01 to 2021-11-30 | $6.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2021-09-01 to 2021-11-30 | −$8.1m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2021-09-01 to 2021-11-30 | −$8.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-09-01 to 2021-11-30 | $0.22 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months, 2021-09-01 to 2021-11-30 | −$6.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2021-11-30 | $31.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-11-30 | $152.3m | us-gaap:AssetsCurrent |
| Total assets | at 2021-11-30 | $182.4m | us-gaap:Assets |
| Current liabilities | at 2021-11-30 | $7.7m | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2021-11-30 | $11.7m | us-gaap:LongTermDebt |
| Shareholders' equity | at 2021-11-30 | $170.2m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1176309/000121390022001563/f10q1121_oramedpharma.htm

Filed Jan 11, 2022.
Source: SEC EDGAR, the filing index for accession 0001213900-22-001563. Last ingested by Listed: Nov 15, 2026, 04:14 ET. No prices; not investment advice.
